Sebastian Loos
Dr. med.
Sebastian Loos
  • Senior physician
  • Medical Specialist in Pediatrics and Youth Medicine
Working area



O45 , 1st Floor
German (Mother tongue)

Areas of expertise



  • 2024
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Volume expansion mitigates Shiga toxin-producing E. coli-hemolytic uremic syndrome in children
Böckenhauer J, Schild R, Kemper M, Henne T, Stein M, Oh J, Loos S
PEDIATR NEPHROL. 2024;39(6):1901-1907.

Case report: Early onset de novo FSGS in a child after kidney transplantation-a successful treatment
Carvajal Abreu K, Loos S, Fischer L, Pape L, Wiech T, Kemper M, Tönshoff B, Oh J, Schild R
FRONT PEDIATR. 2023;11:.

Long-term outcome after combined or sequential liver and kidney transplantation in children with infantile and juvenile primary hyperoxaluria type 1
Loos S, Kemper M, Schmaeschke K, Herden U, Fischer L, Hoppe B, Levart T, Grabhorn E, Schild R, Oh J, Brinkert F
FRONT PEDIATR. 2023;11:.

A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants
Malakasioti G, Iancu D, Milovanova A, Tsygin A, Horinouchi T, Nagano C, Nozu K, Kamei K, Fujinaga S, Iijima K, Sinha R, Basu B, Morello W, Montini G, Waters A, Boyer O, Yıldırım Z, Yel S, Dursun İ, McCarthy H, Vivarelli M, Prikhodina L, Besouw M, Chan E, Huang W, Kemper M, Loos S, Prestidge C, Wong W, Zlatanova G, Ehren R, Weber L, Chehade H, Hooman N, Tkaczyk M, Stańczyk M, Miligkos M, Tullus K
KIDNEY INT. 2023;103(5):962-972.

A link between Krüppel-like factor 4, complement activation, and kidney damage
Karpman D, Loos S
KIDNEY INT. 2022;102(1):14-16.

Response to Battaglia and Balestracci
Loos S
PEDIATR NEPHROL. 2022;37(2):465.

Safety of Therapeutic Apheresis in Children and Adolescents
Taylan C, Schaaf A, Dorn C, Schmitt C, Loos S, Kanzelmeyer N, Pape L, Müller D, Weber L, Thumfart J
FRONT PEDIATR. 2022;10:.

IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection
Tontanahal A, Sperandio V, Kovbasnjuk O, Loos S, Kristoffersson A, Karpman D, Arvidsson I
FRONT IMMUNOL. 2022;13:.

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis
Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio B, Kirschstein M, Hennies I, Pohl M, Häffner K
PEDIATR NEPHROL. 2021;36(2):463-471.

Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)
Loos S, Oh J, Loo L, Kemper M, Blohm M, Schild R
PEDIATR NEPHROL. 2021;36(11):3777-3783.

Heterogeneous Recommendations for School Attendance in Children With Chronic Kidney Diseases During the COVID-19 Pandemic in Europe
Schild R, Hopf L, Loos S, Oh J, Levtchenko E

Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism
Johansson K, Ståhl A, Arvidsson I, Loos S, Tontanahal A, Rebetz J, Chromek M, Kristoffersson A, Johannes L, Karpman D
SCI REP-UK. 2019;9(1):14362.

Causes of renal oligohydramnios - impact on prenatal counseling and postnatal outcome
Loos S, Kemper M
PEDIATR NEPHROL. 2018;33(4):541-545.

Eculizumab in STEC-HUS - need for a proper randomized controlled trial
Loos S, Oh J, Kemper M
PEDIATR NEPHROL. 2018;33(8):1277-1281.

Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome
Beneke J, Sartison A, Kielstein J, Haller H, Nitschke M, Kunzendorf U, Loos S, Kemper M, Stahl R, Menne J
TRANSFUS MED REV. 2017;31(1):51-55.

Haemolytic uraemic syndrome
Karpman D, Loos S, Tati R, Arvidsson I
J INTERN MED. 2017;281(2):123-148.

Case report - atypical hemolytic uremic syndrome triggered by influenza B
Kobbe R, Schild R, Christner M, Oh J, Loos S, Kemper M
BMC NEPHROL. 2017;18(1):96.

Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4
Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau M, Schild R, Lemke J, Beringer O, Müller D, Härtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper M
CLIN INFECT DIS. 2017;64(12):1637-1643.

Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli-Infected Mice
Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson A, Englund E, Chromek M, Karpman D
J IMMUNOL. 2016;197(4):1276-86.

Langzeitverlauf nach STEC-HUS Epidemie (2011) assoziiert mit Shiga-Toxin produzierenden E.coli O104:H4 in Deutschland: erste Ergebnisse
Aulbert W, Loos S, Kranz B, Konrad M, Wigger M, Staude H, Krause M, Müller D, Lemke J, Beringer O, Kropp F, Haffner D, Pape L, Ahlenstiel-Grunow T, Hoppe B, Oh J, Kemper M
2015. Nieren- und Hochdruckkrankheiten. 2. ed. Dustri-Verlag, 39-110.

Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome
He X, Quiñones B, Loo M, Loos S, Scavia G, Brigotti M, Levtchenko E, Monnens L
ACTA PAEDIATR. 2015;104(12):e564-8.

Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions
Karpman D, Ståhl A, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson A, Mossberg M, Kahn R
ADV EXP MED BIOL. 2015;865:19-42.

A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles
Ståhl A, Arvidsson I, Johansson K, Chromek M, Rebetz J, Loos S, Kristoffersson A, Békássy Z, Mörgelin M, Karpman D
PLOS PATHOG. 2015;11(2):e1004619.

Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome
Bauer A, Loos S, Wehrmann C, Horstmann D, Donnerstag F, Lemke J, Hillebrand G, Löbel U, Pape L, Haffner D, Bindt C, Ahlenstiel T, Melk A, Lehnhardt A, Kemper M, Oh J, Hartmann H
PEDIATR NEPHROL. 2014;29(9):1607-1615.

Therapie des hämolytisch-urämischen Syndroms
Lemke J, Kemper M, Loos S
Päd Praxis. 2014;83(1):103-111.

Das Hämolytisch Urämische Syndrom im Kindesalter
Loos S, Oh J, Kemper M
NIEREN HOCHDRUCK. 2013;42(3):126-133.

Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.
Lehnhardt A, Dunst F, Van Husen M, Loos S, Oh J, Eiermann T, Koch M, Kemper M
PEDIATR NEPHROL. 2012;27(8):1389-1395.

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.
Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper M
CLIN INFECT DIS. 2012;55(6):753-759.

Fibroblast growth factor 23 and calcium phosphate homeostasis after pediatric renal transplantation.
Van Husen M, Lehnhardt A, Fischer A, Brinkert F, Loos S, Oh J, Kemper M
PEDIATR TRANSPLANT. 2012;16(5):443-450.

Desperately seeking diarrhoea: outbreak of haemolytic uraemic syndrome caused by emerging sorbitol-fermenting shiga toxin-producing Escherichia coli O157:H-, Germany, 2009.
Nielsen S, Frank C, Fruth A, Spode A, Prager R, Graff A, Plenge-Bönig A, Loos S, Lütgehetmann M, Kemper M, Müller-Wiefel D, Werber D
ZOONOSES PUBLIC HLTH. 2011;58(8):567-572.

Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4.
Rohde H, Qin J, Cui Y, Li D, Loman N, Hentschke M, Chen W, Pu F, Peng Y, Li J, Xi F, Li S, Li Y, Zhang Z, Yang X, Zhao M, Wang P, Guan Y, Cen Z, Zhao X, Christner M, Kobbe R, Loos S, Oh J, Yang L, Danchin A, Gao G, Song Y, Li Y, Yang H, Wang J, Xu J, Pallen M, Wang J, Aepfelbacher M, Yang R, Consortium E
NEW ENGL J MED. 2011;365(8):718-724.

Letzte Aktualisierung aus dem FIS: 16.06.2024 - 04:56 Uhr